RE:RE:RE:RE:RE:RE:RE:While we wait....To say it does not hold the road, breathe a little by the nose.
If you reread, I raised a questioning, not an affirmation, or an unequivocal explanation. I'm not looking for excuses for anything.
If I recall a presentation, I think the R & D for the 4050 was around $ 2-3 million for the next year.
We may still have been stuck with a deal that will not unlock. But my point remains that the deal is for the development of the 4050 and the analogs included in the deal:
The funds provided by SRAM are to be used by Prometic to support and further the clinical development of PBI-4050, PBI-4547 and PBI-4425 outside China, which also contributes to de-risking the clinical and regulatory approval process for China. Read more at https://www.stockhouse.com/companies/bullboard?symbol=t.pli&postid=27766633#dmFGfqgTSCspc4VR.99 I also remember that it was a long time coming out of China's cash when there was the deal with Hepalink.
And when I read the NR, what I understand is that you should not expect to have $ 23 million in free cashflow. Also, if I'm right, the management lacks transparency in its cashflow forecasts by including it in full.
There will be an update at the next CC on the subject. I can not wait to hear the explanations.
I have no idea what will happen, and I too would like things to unlock ... It's hard for everyone waiting!
N.B. I hate writing in French on SH, because I do not put any accent and it looks crazy when I read again :-)